Comparing the current results to its competitors, Arcturus Therapeutics Holdings Inc reported Revenue decrease in the 1 quarter 2026 year on year by -92.99 %, despite the revenue increase by the most of its competitors of 4.35 %, recorded in the same quarter.
Arcturus Therapeutics Holdings Inc , slower than the average decrease reported by the company's competitors of -24.06 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -24.06 %
Publicly Traded Peers of Arcturus Therapeutics Holdings Inc
Exicure Inc Share Performance
-60.44%
This Quarter
Exicure Inc
Profile
Exicure Inc operates on a business model focused on developing and commercializing transformative gene therapy drugs utilizing its proprietary spherical nucleic acid (SNA) technology. The company aims to leverage its platform to create therapeutic solutions for various diseases by delivering genetic medicines directly to cells. By collaborating with partners or independently, Exicure Inc aims to advance its pipeline and ultimately bring innovative treatments to the market.
Palatin Technologies Inc has a business model focused on developing and commercializing innovative medicines in the field of reproductive healthcare and sexual dysfunction. The company's revenue streams primarily come from partnerships, licensing agreements, and product sales.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Sources:
Arcturus Therapeutics Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Arcturus Therapeutics Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
